These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Anti-CCR4 monoclonal antibody mogamulizumab for the treatment of EBV-associated T- and NK-cell lymphoproliferative diseases. Kanazawa T; Hiramatsu Y; Iwata S; Siddiquey M; Sato Y; Suzuki M; Ito Y; Goshima F; Murata T; Kimura H Clin Cancer Res; 2014 Oct; 20(19):5075-84. PubMed ID: 25117294 [TBL] [Abstract][Full Text] [Related]
6. Cutaneous T-Cell Lymphoma: Optimizing Care in Patients Receiving Anti-CCR4 Monoclonal Antibody Mogamulizumab. Tawa M; Kopp E; McCann S; Cantrell W Clin J Oncol Nurs; 2019 Aug; 23(4):E73-E80. PubMed ID: 31322628 [TBL] [Abstract][Full Text] [Related]
7. Expression of programmed death-1 in primary cutaneous CD4-positive small/medium-sized pleomorphic T-cell lymphoma, cutaneous pseudo-T-cell lymphoma, and other types of cutaneous T-cell lymphoma. Cetinözman F; Jansen PM; Willemze R Am J Surg Pathol; 2012 Jan; 36(1):109-16. PubMed ID: 21989349 [TBL] [Abstract][Full Text] [Related]
8. Antibody-Based Therapies for Cutaneous T-Cell Lymphoma. Welborn M; Duvic M Am J Clin Dermatol; 2019 Feb; 20(1):115-122. PubMed ID: 30430444 [TBL] [Abstract][Full Text] [Related]
9. Reduction of regulatory T cells by Mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive/refractory mycosis fungoides and Sézary syndrome. Ni X; Jorgensen JL; Goswami M; Challagundla P; Decker WK; Kim YH; Duvic MA Clin Cancer Res; 2015 Jan; 21(2):274-85. PubMed ID: 25376389 [TBL] [Abstract][Full Text] [Related]
10. CD8+ T cells in cutaneous T-cell lymphoma: expression of cytotoxic proteins, Fas Ligand, and killing inhibitory receptors and their relationship with clinical behavior. Vermeer MH; van Doorn R; Dukers D; Bekkenk MW; Meijer CJ; Willemze R J Clin Oncol; 2001 Dec; 19(23):4322-9. PubMed ID: 11731515 [TBL] [Abstract][Full Text] [Related]
11. Primary cutaneous CD8-positive epidermotropic cytotoxic T cell lymphomas. A distinct clinicopathological entity with an aggressive clinical behavior. Berti E; Tomasini D; Vermeer MH; Meijer CJ; Alessi E; Willemze R Am J Pathol; 1999 Aug; 155(2):483-92. PubMed ID: 10433941 [TBL] [Abstract][Full Text] [Related]
12. CCR4 in cutaneous T-cell lymphoma: Therapeutic targeting of a pathogenic driver. Nicolay JP; Albrecht JD; Alberti-Violetti S; Berti E Eur J Immunol; 2021 Jul; 51(7):1660-1671. PubMed ID: 33811642 [TBL] [Abstract][Full Text] [Related]
13. Upregulation of inhibitory signaling receptor programmed death marker-1 (PD-1) in disease evolution from cutaneous lymphoid dyscrasias to mycosis fungoides and Sezary's syndrome. Nguyen GH; Olson LC; Magro CM Ann Diagn Pathol; 2017 Jun; 28():54-59. PubMed ID: 28648940 [TBL] [Abstract][Full Text] [Related]
14. Clinicopathological analysis of 17 primary cutaneous T-cell lymphoma of the γδ phenotype from Japan. Takahashi Y; Takata K; Kato S; Sato Y; Asano N; Ogino T; Hashimoto K; Tashiro Y; Takeuchi S; Masunari T; Hiramatsu Y; Maeda Y; Tanimoto M; Yoshino T Cancer Sci; 2014 Jul; 105(7):912-23. PubMed ID: 24815502 [TBL] [Abstract][Full Text] [Related]
15. Primary cutaneous T-cell lymphomas other than mycosis fungoides and Sézary syndrome. Part I: Clinical and histologic features and diagnosis. Stoll JR; Willner J; Oh Y; Pulitzer M; Moskowitz A; Horwitz S; Myskowski P; Noor SJ J Am Acad Dermatol; 2021 Nov; 85(5):1073-1090. PubMed ID: 33940098 [TBL] [Abstract][Full Text] [Related]
16. Mogamulizumab: An Anti-CC Chemokine Receptor 4 Antibody for T-Cell Lymphomas. Moore DC; Elmes JB; Shibu PA; Larck C; Park SI Ann Pharmacother; 2020 Apr; 54(4):371-379. PubMed ID: 31648540 [No Abstract] [Full Text] [Related]
17. Primary cutaneous T-cell lymphomas other than mycosis fungoides and Sézary syndrome. Part II: Prognosis and management. Oh Y; Stoll JR; Moskowitz A; Pulitzer M; Horwitz S; Myskowski P; Noor SJ J Am Acad Dermatol; 2021 Nov; 85(5):1093-1106. PubMed ID: 33945836 [TBL] [Abstract][Full Text] [Related]
18. Cutaneous T-cell lymphoma (CTCL), rare subtypes: five case presentations and review of the literature. Geller S; Myskowski PL; Pulitzer M; Horwitz SM; Moskowitz AJ Chin Clin Oncol; 2019 Feb; 8(1):5. PubMed ID: 30525759 [TBL] [Abstract][Full Text] [Related]
19. Expression of T-follicular helper markers in sequential biopsies of progressive mycosis fungoides and other primary cutaneous T-cell lymphomas. Bosisio FM; Cerroni L Am J Dermatopathol; 2015 Feb; 37(2):115-21. PubMed ID: 25406852 [TBL] [Abstract][Full Text] [Related]